+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free

Cardiovascular Peptides Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

Pre Book Price: $ 5216

Original Price: $ 5795


Peptides are short chain of amino acids linked by peptide bonds. Usually they contain less than 50 amino acids. Natural cardiovascular peptides such as ANP and BNP are hormones of cardiac origin that play an important role in the regulation of cardiovascular homeostasis. Cardiovascular peptides are predominantly produced in heart, although many other tissues produced it but in amounts inadequate to induce any physiological effects. Advancement in biotechnology and pharmaceutical sciences has enable researchers to modify or mimic naturally occurring peptide for diverse therapeutic uses. One such example is Nesiritide, recombinant form of the 32 amino acid human B-type natriuretic peptide. Cardiovascular peptides are used in primarily to treat or avoid acute myocardial infarction, Coronary Ischemia, hypertension, Cardio metabolic Disease, heart failure, peripheral vascular diseases, and hematologic diseases.


Increasing prevalence of cardiovascular diseases obesity, sedentary lifestyle, serious side effects associated with currently available cardiovascular products and high risk linked with surgical procedures are some major factors driving the cardiovascular peptides market growth. As per the World Health Organization (WHO) statistics on cardiovascular diseases, approximately 17.3 million people died from cardiovascular diseases in 2008, accounting for nearly 30% of all global deaths. The WHO further states that the number of global deaths by cardiovascular diseases is expected to reach 30 million by 2030. Concerted efforts in research and development by pharmaceutical companies and extensive research collaborations would help them gain core competencies in this market. Big pharmaceutical companies such as Eli Lilly & Company, Novo Nordisk, Novartis AG, and Bristol Myers Squibb (BMS) have invested huge money in research and development of cardiovascular peptides. However, high cost associated with development of cardiovascular peptides, strict regulatory policies and FDA approval procedure may impede growth of the cardiovascular peptides market to some extent. Furthermore, availability of alternate treatment options is one of the key challenges for global cardiovascular peptides market.


The cardiovascular peptides market has been analyzed on the basis of major cardiovascular diseases such as heart failure, myocardial infarction, hypertension, peripheral vascular diseases and hematologic Diseases. Many of the cardiovascular peptides are in clinical trials. Danegaptide, a novel dipeptide, invented by Zealand, is a potent and selective gap junction modifier. Currently this drug is in the Phase II Proof-of-Concept study to evaluate the efficacy and safety in patients with an acute myocardial infarction (AMI).


Geographically, the global cardiovascular peptides market has been segmented into North America, Europe, Asia-Pacific and Rest of World (RoW). North America dominates the global cardiovascular peptides market owning to high prevalence rate of cardiovascular diseases, huge healthcare expenditure, insurance coverage and sophisticated diagnostic technologies for cardiac manifestations. According to the American Heart Association, 650,000 new cases of cardiac diseases are diagnosed every year in U.S. In Europe, cardiovascular diseases are most prevalent in Central and Eastern Europe. As per European Society of Cardiology, in 2012, cardiovascular diseases accounted for 4 million deaths in Europe, nearly 47% of all deaths.  In Asia-Pacific region, particularly India and China are the fastest growing markets for cardiovascular peptide therapeutics owning to large population base and increasing elderly population. 


Some of the major players in cardiovascular peptides market include Eli Lilly & Company, Novo Nordisk, Novartis AG, AstraZeneca, and plc, Bristol Myers Squibb, GlaxoSmithKline, Takeda Pharmaceutical, Zealand Pharma, Diartis Pharmaceuticals, American Peptide Company, Inc., Capstone Therapeutics and Nile Therapeutics, Inc.


This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. This report provides comprehensive analysis of 

  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis. 


Reasons for Buying this Report

  • This report provides pin-point analysis for changing competitive dynamics
  • It provides a forward looking perspective on different factors driving or restraining market growth 
  • It provides a six-year forecast assessed on the basis of how the market is predicted to grow 
  • It helps in understanding the key product segments and their future
  • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
  • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments 
  • It provides distinctive graphics and exemplified SWOT analysis of major market segments 

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

To receive discount, please click on the button below.

Please click on the button below to customize this report.

Back To Top